Table 1.

Participant characteristics of the 48 Malawian women who initiated the levonorgestrel implant, stratified by efavirenz use

Participant characteristicsa	Efavirenz nonusers (n = 12)	Efavirenz users (n = 30)
Median age (years)	26 (23–31)	34 (29–38)
Weight (kg)	54 (49–59)	57 (53–64)
HIV-infected, n (%)	0 (0)	30 (100)
Median number of living children	2 (2–3)	2.5 (2–3)
Married, n (%)	10 (83)	19 (63)
Less than primary education, n (%)	5 (42)	13 (43)
Reported prior use of hormonal contraception, n (%)	9 (75)	22 (73)
Reported that they had vaginal sex since last visit, n (%)^b
Reported at 0%–25% of visits	1 (8)	4 (14)
Reported at 26%–50% visits	1 (8)	2 (7)
Reported at 50%–75% visits	2 (17)	8 (28)
Reported at 76%–100% visits	8 (67)	15 (52)
Among those that reported vaginal sex since last visit, reported that they always used a condom since last visit^b
Reported at 0%–25% of visits	9 (75)	4 (14)
Reported at 26%–50% visits	2 (17)	8 (28)
Reported at 50%–75% visits	0 (0)	5 (12)
Reported at 76%–100% visits	1 (8)	12 (41)
For HIV-infected women only:	n = 0	n = 30
Time since HIV diagnosis (years)	N/A
< 5 years		19 (63)
5–10 years		9 (30)
> 10 years		2 (7)
Time on antiretroviral medication (years)c	N/A
< 1 year		5 (17)
1–5 years		17 (59)
> 5 years		7 (24)
Median CD4 + T-cell count	N/A	282 (194–451)
Median HIV viral load	N/A	0 (0–1087)

Data are presented as either median (interquartile range) or n (%), as appropriate.

^aData were obtained from baseline interview unless marked with ^.

^bResponse missing for one efavirenz user because she never responded to these questions.

^cTime on antiretroviral medication was missing for one efavirenz user.